- Shares of Navidea Biopharmaceuticals (NAVB -4.3%) trade lower out of the gate.
- Behind the move looks to be Aegis, where, according to market chatter, analysts have cut their price target.
- Reminder: Q3 Lymphoseek sales were $144K.
- In other company news, NAVB says it will collaborate with the University of San Francisco "on a clinical study to evaluate, for the first time, the use and performance of technetiumlabeled tilmanocept in patients with Kaposi Sarcoma." (PR)
Navidea Biopharmaceuticals falls as Aegis cuts target
Nov 13 2013, 09:39 ET